For a woman with a history of diabetes and hypertension after a recent myocardial infarction, what should be added to her treatment to prevent ASCVD?

Study for the Board Certified Cardiology Pharmacist Exam. Utilize flashcards and answer multiple-choice questions with detailed explanations. Prepare efficiently for your certification!

The correct choice in this context is the addition of icosapent ethyl at a dosage of 2 grams by mouth twice daily. This treatment is primarily used for its cardiovascular protection properties, especially in patients with a history of cardiovascular events, such as a myocardial infarction, along with other risk factors like diabetes and hypertension.

Icosapent ethyl, an omega-3 fatty acid, has been shown in clinical studies to significantly reduce the risk of major adverse cardiovascular events (MACE) in patients with elevated triglycerides who are already on statin therapy. The reduction observed in cardiovascular events can help prevent atherosclerotic cardiovascular disease (ASCVD) post-myocardial infarction, making it a suitable option for this patient.

In contrast, while other options may have some role in lipid management, they do not address the ASCVD prevention as effectively in this specific patient scenario. For instance, ezetimibe primarily lowers LDL cholesterol and is generally used in conjunction with statins, but may not have the same level of evidence supporting its role in preventive care post-MI. Niacin, though previously utilized for lipid management, has fallen out of favor due to its side effects and lack of clear benefit in ASCVD prevention in

Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy